vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and Axalta Coating Systems Ltd. (AXTA). Click either name above to swap in a different company.

Axalta Coating Systems Ltd. is the larger business by last-quarter revenue ($1.3B vs $950.5M, roughly 1.3× Astrana Health, Inc.). Axalta Coating Systems Ltd. runs the higher net margin — 4.8% vs 0.7%, a 4.1% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -3.7%). Axalta Coating Systems Ltd. produced more free cash flow last quarter ($286.0M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -1.2%).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Axalta Coating Systems Ltd., also known as simply Axalta, is an American company specializing in coatings in a wide variety of industrial applications, materials and sectors, including automotive paints. The company is based in Philadelphia, Pennsylvania, and incorporated in Bermuda. Axalta develops and manufactures coatings for light and commercial vehicles, industrial, and refinish applications. The firm does business in 130 countries, has nearly 13,000 employees, and has more than 100,000 ...

ASTH vs AXTA — Head-to-Head

Bigger by revenue
AXTA
AXTA
1.3× larger
AXTA
$1.3B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+46.6% gap
ASTH
42.9%
-3.7%
AXTA
Higher net margin
AXTA
AXTA
4.1% more per $
AXTA
4.8%
0.7%
ASTH
More free cash flow
AXTA
AXTA
$291.9M more FCF
AXTA
$286.0M
$-6.0M
ASTH
Faster 2-yr revenue CAGR
ASTH
ASTH
Annualised
ASTH
53.3%
-1.2%
AXTA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTH
ASTH
AXTA
AXTA
Revenue
$950.5M
$1.3B
Net Profit
$6.6M
$60.0M
Gross Margin
33.4%
Operating Margin
1.9%
12.8%
Net Margin
0.7%
4.8%
Revenue YoY
42.9%
-3.7%
Net Profit YoY
184.4%
-56.2%
EPS (diluted)
$0.12
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
AXTA
AXTA
Q4 25
$950.5M
$1.3B
Q3 25
$956.0M
$1.3B
Q2 25
$654.8M
$1.3B
Q1 25
$620.4M
$1.3B
Q4 24
$665.2M
$1.3B
Q3 24
$478.7M
$1.3B
Q2 24
$486.3M
$1.4B
Q1 24
$404.4M
$1.3B
Net Profit
ASTH
ASTH
AXTA
AXTA
Q4 25
$6.6M
$60.0M
Q3 25
$373.0K
$110.0M
Q2 25
$9.4M
$109.0M
Q1 25
$6.7M
$99.0M
Q4 24
$-7.8M
$137.0M
Q3 24
$16.1M
$101.0M
Q2 24
$19.2M
$112.0M
Q1 24
$14.8M
$41.0M
Gross Margin
ASTH
ASTH
AXTA
AXTA
Q4 25
33.4%
Q3 25
34.9%
Q2 25
35.0%
Q1 25
34.3%
Q4 24
34.1%
Q3 24
35.0%
Q2 24
34.0%
Q1 24
33.2%
Operating Margin
ASTH
ASTH
AXTA
AXTA
Q4 25
1.9%
12.8%
Q3 25
2.0%
15.8%
Q2 25
3.1%
14.8%
Q1 25
3.3%
13.9%
Q4 24
0.1%
14.3%
Q3 24
5.9%
14.6%
Q2 24
6.2%
15.2%
Q1 24
7.5%
9.4%
Net Margin
ASTH
ASTH
AXTA
AXTA
Q4 25
0.7%
4.8%
Q3 25
0.0%
8.5%
Q2 25
1.4%
8.4%
Q1 25
1.1%
7.8%
Q4 24
-1.2%
10.5%
Q3 24
3.4%
7.7%
Q2 24
3.9%
8.3%
Q1 24
3.7%
3.2%
EPS (diluted)
ASTH
ASTH
AXTA
AXTA
Q4 25
$0.12
$0.28
Q3 25
$0.01
$0.51
Q2 25
$0.19
$0.50
Q1 25
$0.14
$0.45
Q4 24
$-0.14
$0.63
Q3 24
$0.33
$0.46
Q2 24
$0.40
$0.51
Q1 24
$0.31
$0.18

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
AXTA
AXTA
Cash + ST InvestmentsLiquidity on hand
$429.5M
$657.0M
Total DebtLower is stronger
$3.2B
Stockholders' EquityBook value
$779.3M
$2.3B
Total Assets
$2.2B
$7.6B
Debt / EquityLower = less leverage
1.36×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
AXTA
AXTA
Q4 25
$429.5M
$657.0M
Q3 25
$463.4M
$606.0M
Q2 25
$342.1M
$625.0M
Q1 25
$260.9M
$575.0M
Q4 24
$290.8M
$593.0M
Q3 24
$350.3M
$567.0M
Q2 24
$327.7M
$840.0M
Q1 24
$337.3M
$624.0M
Total Debt
ASTH
ASTH
AXTA
AXTA
Q4 25
$3.2B
Q3 25
$3.4B
Q2 25
$3.4B
Q1 25
$3.4B
Q4 24
$3.4B
Q3 24
$3.5B
Q2 24
$3.6B
Q1 24
$3.4B
Stockholders' Equity
ASTH
ASTH
AXTA
AXTA
Q4 25
$779.3M
$2.3B
Q3 25
$775.5M
$2.3B
Q2 25
$765.5M
$2.3B
Q1 25
$745.4M
$2.1B
Q4 24
$712.7M
$1.9B
Q3 24
$704.6M
$1.9B
Q2 24
$678.9M
$1.8B
Q1 24
$653.5M
$1.7B
Total Assets
ASTH
ASTH
AXTA
AXTA
Q4 25
$2.2B
$7.6B
Q3 25
$2.2B
$7.8B
Q2 25
$1.4B
$7.8B
Q1 25
$1.3B
$7.4B
Q4 24
$1.4B
$7.2B
Q3 24
$1.3B
$7.5B
Q2 24
$1.3B
$7.3B
Q1 24
$1.2B
$7.1B
Debt / Equity
ASTH
ASTH
AXTA
AXTA
Q4 25
1.36×
Q3 25
1.48×
Q2 25
1.50×
Q1 25
1.64×
Q4 24
1.78×
Q3 24
1.84×
Q2 24
2.02×
Q1 24
1.97×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
AXTA
AXTA
Operating Cash FlowLast quarter
$-2.9M
$344.0M
Free Cash FlowOCF − Capex
$-6.0M
$286.0M
FCF MarginFCF / Revenue
-0.6%
22.7%
Capex IntensityCapex / Revenue
0.3%
4.6%
Cash ConversionOCF / Net Profit
-0.44×
5.73×
TTM Free Cash FlowTrailing 4 quarters
$104.5M
$453.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
AXTA
AXTA
Q4 25
$-2.9M
$344.0M
Q3 25
$10.0M
$137.0M
Q2 25
$90.9M
$142.0M
Q1 25
$16.6M
$26.0M
Q4 24
$-10.9M
$234.0M
Q3 24
$34.0M
$194.0M
Q2 24
$23.2M
$114.0M
Q1 24
$6.0M
$34.0M
Free Cash Flow
ASTH
ASTH
AXTA
AXTA
Q4 25
$-6.0M
$286.0M
Q3 25
$7.4M
$87.0M
Q2 25
$89.5M
$97.0M
Q1 25
$13.6M
$-17.0M
Q4 24
$-13.5M
$172.0M
Q3 24
$31.7M
$161.0M
Q2 24
$20.4M
$91.0M
Q1 24
$5.6M
$12.0M
FCF Margin
ASTH
ASTH
AXTA
AXTA
Q4 25
-0.6%
22.7%
Q3 25
0.8%
6.8%
Q2 25
13.7%
7.4%
Q1 25
2.2%
-1.3%
Q4 24
-2.0%
13.1%
Q3 24
6.6%
12.2%
Q2 24
4.2%
6.7%
Q1 24
1.4%
0.9%
Capex Intensity
ASTH
ASTH
AXTA
AXTA
Q4 25
0.3%
4.6%
Q3 25
0.3%
3.9%
Q2 25
0.2%
3.4%
Q1 25
0.5%
3.4%
Q4 24
0.4%
4.7%
Q3 24
0.5%
2.5%
Q2 24
0.6%
1.7%
Q1 24
0.1%
1.7%
Cash Conversion
ASTH
ASTH
AXTA
AXTA
Q4 25
-0.44×
5.73×
Q3 25
26.69×
1.25×
Q2 25
9.65×
1.30×
Q1 25
2.48×
0.26×
Q4 24
1.71×
Q3 24
2.11×
1.92×
Q2 24
1.21×
1.02×
Q1 24
0.40×
0.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

AXTA
AXTA

Refinish$509.0M40%
Light Vehicle$372.0M29%
Industrial$282.0M22%
Commercial Vehicle$99.0M8%

Related Comparisons